NCT02858310View on ClinicalTrials.gov

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

January 27, 2017

Primary Completion Date

July 2, 2025

Study Completion Date

July 2, 2025

Conditions
Papillomavirus InfectionsCervical Intraepithelial NeoplasiaCarcinoma In SituVulvar NeoplasmsVulvar Diseases
Interventions
BIOLOGICAL

E7 TCR cells

T cells genetically engineered with a TCR targeting HPV-16 E7 (E7 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells

DRUG

Aldesleukin

Following cell infusion the patient receives high-dose bolus aldesleukin, which is dosed to individual patient tolerance. Aldesleukin improves the survival of E7 TCR cells after infusion.

DRUG

Fludarabine

Part of the non-myeloablative lymphocyte-depleting preparative regimen.

DRUG

Cyclophosphamide

Part of the non-myeloablative lymphocyte-depleting preparative regimen.

Trial Locations (2)

20892

National Institutes of Health Clinical Center, Bethesda

08901

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02858310 - E7 TCR T Cells for Human Papillomavirus-Associated Cancers | Biotech Hunter | Biotech Hunter